07:06

KRAS downregulates FAS (death cell receptor) expression on pancreatic cancer cells #Code: 724

11:30

Effect KRAS mutation on the T-cells and myeloid cells #Code: 723

05:17

Eradication of pancreatic tumors after elimination of KRAS mutation #Code: 722

09:08

Effect of RMC-7977 on native models of Pancreatic cancer (PDAC) #Code: 721

06:54

RMC-7977 selectivity towards the tumours #Code: 720

07:35

Pharmacology of RAS dependence of RMC-7977 #Code: 719

06:19

RMC-7977 exhibits anti-tumor activity against Pancreatic cancer (PDAC) in-vivo #Code: 718

06:50

RMC-7977 (Ras-inhibitor) exhibits anti-tumor activity against Pancreatic cancer (PDAC) #Code: 717

05:51

Overview of enhanced CAR T-cell Immunotherapy against solid malignancy (Ovarian Cancer) #Code: 716

12:32

Improved efficiency of CAR T-cell Immunotherapy against solid malignancy (Ovarian Cancer) #Code: 715

10:08

TAGLN2 helps in T cell metabolic fitness #Code: 714

14:24

ER stress (XBP1s) cause low expression of TAGLN2 on cell surface of CD8+T-cells #Code: 713

13:49

TAGLN2 assists FABP5 in activated CD8+Tcells for lipid uptake in ovarian cancer condition #Code: 712

09:58

Ovarian Cancer disrupts CD8+T (CAR-T) cell's via downregulating FABP5 surface expression #Code: 711

07:58

DANA effect on Calcium oscillation, sialic acid & comparison with sialidase isoenzyme Neu3 #Code:710

05:15

DANA effect on Blood Glucose and Plasma insulin levels in-vivo in the absence of glucose #Code: 709

06:02

Blood Glucose and Plasma insulin levels are affected by DANA #Code: 708

05:49

DANA, a sialidase inhibitor, could be potential anti-diabetic treatment #Code: 707

06:59

DiaBZl stimulates NY-ESO-1 antigen expression in-vivo #Code: 706

06:34

STING agonist DiaBZl along with engineered T cells impairs tumor growth #Code: 705

05:22

DiaBZl stimulates NY-ESO-1 antigen expression on tumor cells #Code: 704

06:24

DiaBZl stimulates tumor Apoptosis #Code: 703

05:43

DiaBZl stimulates TCR signaling in High Affinity engineered T cells (HATs) #Code: 702

05:21

DiaBZl stimulates sting signaling pathways in High Affinity engineered T cells (HATs) #Code: 701

06:27

Effects of DiaBZl on T-cell engineered with IG4HA-T on cytotoxicity against tumor cells #Code: 700

07:08

DiaBZl increases T-cell cytotoxicity against tumor cells by STING #Code: 699

08:05

sTRA & CA19-9 helps in predicting the time to progress (TTP) of PDAC #Code: 698

07:47

sTRA & CA19-9 dual expression on PDAC often represent Secretory epithelia & vice-versa #Code: 697

06:44

sTRA & CA19-9 glycans express on cultured pancreatic cancer cells #Code: 696

07:12

sTRA & CA19-9 glycans express non-identical subset of pancreatic cancer cell populations #Code: 695

08:40

sTRA glycans express independent of CA19-9 glycans on pancreatic cancer (PDAC) #Code: 694

06:17

sTRA glycan could be the potential biomarker for pancreatic cancer apart from CA19-9 #Code: 693

07:13

B4ST6FC (Glycosyltransferase engineered antibody) has better therapeutic results on mice #Code: 692

07:22

Role of platelets in in-vivo sialylation #Code: 691

05:51

Site-specific sialylation of B4ST6FC results in antiinflammation response #Code: 690

06:26

Enzyme activity (sialyltransferase) responsible for reduced inflammation #Code: 689

06:28

In-vivo sialylation to suppress inflammation #Code: 688

08:02

In-vivo validation of Anti-inflammatory function of engineered antibody #Code: 687

07:23

Anti-inflammatory antibody using engineered glycosyltransferases #Code: 686

06:35

Pancreatic Cancer cells drug response in ex-vivo models #Code: 685

06:46

In-vivo and Ex-vivo PDAC matrisome analysis #Code: 684

05:39

Matrisome Recapitulation in Ex-vivo models on PDAC #Code: 683

07:07

Tunability of PA-ECM in-vitro hydrogel towards PDAC cultures #Code: 682

07:42

Different ex-vivo model comparisons towards PDAC in-vivo behavior #Code: 681

07:18

Transcriptome analysis to compare ex-vivo models with human pancreatic cancer tissue #Code: 680

06:34

Validating the custom design PA-ECM: 3D invitro model to replicate in vivo PDAC behaviour #Code: 679

07:14

Characterization & design of PA-ECM: 3D invitro model to replicate in vivo PDAC behaviour #Code: 678

08:48

Stiffness mediated chemoresistance in PDAC #Code: 677

08:17

HA-CD44 interactions in high HELP mediates chemoresistance in PDAC #Code: 676

06:22

HA in high HELP mediates chemoresistance in PDAC #Code: 675

08:07

Drug efflux transporter (ABCG2) mediates chemoresistance in PDAC #Code: 674

08:06

Long-term effect of stiff matrix to chemoresistance in pancreatic tumor #Code: 673

08:45

Tumor-matrix (Extra-cellular matrix) contributes to chemoresistance in pancreatic tumor #Code: 672

05:56

Clinical Relevance of VCAM-1 and CCL18 on Pancreatic Cancer (PDAC) prognosis #Code: 671

05:36

VCAM-1 helps in proliferation of the Pancreatic Cancer (PDAC) #Code: 670

07:43

Lactate mediates polarization of the macrophages (in-vitro) #Code: 669

06:54

VCAM-1 modulates Warburg effect of PDAC cells in vitro #Code: 668

05:29

VCAM-1 modulates migration and invasion of PDAC #Code: 667

05:20

VCAM-1 mediates proliferation & cell cycle checkpoint at G1-S in Pancreatic Cancer cells #Code: 666

05:40

VCAM-1 overexpressed in PDAC patients and PDAC cell lines #Code: 665